openPR Logo
Press release

Companion Diagnostics Market Share, Trends Analysis: 2017-2021

07-20-2017 03:29 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: SA-BRC

Companion Diagnostics Market Share, Trends Analysis:

Companion diagnostics has revolutionized cancer therapeutics and enabled physicians to select specific treatment pattern from of myriad of drugs for cancer treatment. This has improved treatment outcome manyfold and has now become and indispensable part of personalized medicine. The companion diagnostics market received great attention post success of Herceptin (trastuzumab) and Gleevec (imatinib). Rapid adoption of companion diagnostics and supportive regulatory agencies have encouraged researchers to seek molecules that target specific gene segments. Increasing know how of cancer biomarkers has also supported companion diagnostics market growth.

The U.S. FDA has defines companion diagnostics as tool or imaging device that provides information that is essential for safe and effective corresponding treatment. In 2015 the regulatory agency approved Tagrisso (osimertinib) by AstraZeneca or treatment of lung cancer patients. The agency also approved a corresponding test by Roche Cobas EGFR Mutation Test v2 for identification of EGFR exon 19 deletions or L858R mutations that are target patients for the newly approved drug. Pharmaceutical companies globally are trying to develop targeted therapies for efficient cancer treatment. According to an article published by Forbes, over 85% of the drugs in AstraZeneca?s developmental pipeline are directed towards personalized care. Various biotechnology companies are also engaged in collaborative agreements with pharmaceutical companies for development of companion diagnostic tests. In 2016, NanoString Technologies collaborated with Medivation and Astellas for development of novel companion diagnostic test. These factors would leverage companion diagnostics market growth globally.

Request Free Report Sample@ www.sa-brc.com/Global-Companion-Diagnostics-Market-Assess...

Cancer has become a global crisis with increasing mortality rate in mid- and low-income countries. National Cancer Institute, U.S. estimates over 1.68 million new cancer cases diagnosed in the U.S. in 2016. In U.K. 0.35 million new cancer cases were recorded according to Cancer Research U.K. Globally more than 8 million patients die due to cancer. Breast cancer prevalence studies in India indicate that the breast cancer incidence rate has increased dramatically from 7% in 1990 to 16% in 2015 among age group 30 to 40 years. China also records high prevalence of breast cancer with over 187,000 new breast cancer cases diagnosed in 2012, which accounts for 12% of the global breast cancer cases. Increasing cancer prevalence, rise in cost of treatment and increasing inconvenience from side effects of chemotherapy drugs has demanded targeted therapy that can be improve treatment outcomes with fewer side effects. These unmet needs are accurately targeted by personalized medicine, thus boosting the companion diagnostics market.

Key players in the companion diagnostics market include Abbott Laboratories, BioGenex Laboratories Inc., GE Healthcare Ltd., bioM?rieux SA, Agendia N.V., Qiagen N.V., Roche Holdings AG, Siemens Healthcare, Thermo Fisher Scientific, Inc., and PerkinElmer, Inc. among others.

Request For TOC@ www.sa-brc.com/Global-Companion-Diagnostics-Market-Assess...

NOTE: This report is currently under research and will be made available to clients on request.

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
Office No. 14,
Hermes Kunj, Mangaldas Road,
Pune, 411001
India
Phone: +91-02041210872
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Companion Diagnostics Market Share, Trends Analysis: 2017-2021 here

News-ID: 633542 • Views: 271

More Releases from SA-BRC

Biochip Market Analysis by Application and Trend 2017-2021
Biochips allow simultaneous testing of higher number of analytes to achieve high throughput and low cost per test. Nanotechnology has helped in miniaturization of devices to achieve higher performance standards. Microarrays are most important part of biochips which send signals to the biochip to deliver end results. Microfluidic biochips have become modern alternative to routine laboratories. Microfluidic technology which enables controlling flow of liquids in micro and pico quantities has
Acute Myeloid Leukemia Therapeutics Market Share, Analysis and Segments 2017-202 …
Acute myeloid leukemia is a cancer of blood cells and involves proliferation of abnormal blood cell types and subsequent replacement of bone marrow with cancerous cells. Major leukemia types include myeloblastic, promyeloctic, myelomonocytic, monocytic, erythroleukemia, megakaryocytic. Treatment of leukemia mainly depends on the type of leukemia and stage. Acute myeloid leukemia therapeutics market is rich with branded as well as generic drugs classified under various classes including antineoplastic agents, corticosteroids, tyrosine
North America and Europe Bionic Eye Market Segment Analysis And Forecast: 2017-2 …
Sudden surge in bionic eye market was experienced recently after the National Health Service (NHS) announced the sponsorship to implant bionic eyes in ten patients. The bionic eye can help regain vision in individuals with visual impairment. Although currently two bionic eye systems has received regulatory approvals, other companies in the bionic eye market are also trying to develop new technology that can help in regaining visual sense in patients. The
Global Antidiabetic Drugs Market - Product Segment Analysis And Forecast
Diabetes is a major lifestyle disorder affecting millions of individuals globally. The disorder is also linked with other complications such as diabetic retinopathy, diabetic foot ulcers, nephropathy and cardiovascular complications among others. Wide spread global prevalence and rising incidence rate has made the antidiabetic drugs market attractive for pharmaceutical drug manufacturers. Introduction of superior products in the recent past and increasing patient compliance are other factors driving the diabetes treatment

All 5 Releases


More Releases for Companion

Companion Diagnostics Market – Growth , Opportunities and Applications
Companion diagnostics are tests to understand which patient can be benefited from a certain drug or what dosage should be prescribed based upon patient’s clinical diagnosis, which provides evidence required for the successful and harmless use of an equivalent drug or biological product to treat the medical condition. These are medical instruments that support doctors to elect which treatment and dosage should be given to patients personalized to their necessity. Companion
A Smart Companion to your TV
Following HELLO’s very successful Kickstarter campaign (1339% funded), Solaborate is launching the new and improved HELLO 2 on Kickstarter, along with HELLO Touch TV, HELLO Creator Edition and 2 Gadget Extensions. A Smart Companion to your TV HELLO 2, like its predecessor, turns any TV into a video communication and collaboration device. HELLO 2 does everything users love about the original even better with Alexa support, home automation (Zigbee), and Android games,
Global Companion Diagnostics Market
The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to improve the time to market for companion diagnostic (CDx) test
Global Farm & Companion Animal Health Market
Veterinary healthcare products include pharmaceuticals, nutrition (feed additives) and devices for both companion and livestock animals. Companion animals include pets such as dogs, cats and horses; although in recent years the market has expanded reasonably for avian pets, reptiles and exotic fish. The healthcare products have transformed the health and quality of life for millions of pets across the world. The greatest challenge of maintaining pets is seeking the keenness
Global Companion Diagnostics Market to Grow Globally
Companion diagnostic (CDx) is a diagnostic tool used to determine the suitability of a drug therapy to the patient. It has become a critical part of targeted cancer therapy that allows for development of personalized therapy can be developed and administered to the patient. Whole blood samples, tissues samples, or buccal samples are collected and tested for diagnosis and identification of targeted disease biomarker. CDx is usually utilized in identifying
Global Companion Diagnostics – Growth Companion for Personalized Medicine
Companion Diagnostics: Growth Companion for Personalized Medicine Personalized medicine is the new segment in discussion among healthcare experts around the globe. Also, encouragement from the regulatory bodies such as the FDA and EMEA in erms of providing a defined structure for companion diagnostic development is driving research activities in personalized medicine. Diagnosis at molecular level for each individual is of prime importance to identify the target biomarker before deciding the therapy.